| Trial ID: | L3906 |
| Source ID: | NCT01647308
|
| Associated Drug: |
Isis-Apociiirx
|
| Title: |
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: ISIS-APOCIIIRX|DRUG: Placebo
|
| Outcome Measures: |
Primary: Total apoC-III, The effect of treatment with ISIS ISIS-APOCIIIRX or Placebo on fasting total apoC-III levels., 91 Days | Secondary: Insulin Sensitivity, Change from baseline in insulin sensitivity, Day 92
|
| Sponsor/Collaborators: |
Sponsor: Ionis Pharmaceuticals, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-07
|
| Completion Date: |
2014-03
|
| Results First Posted: |
|
| Last Update Posted: |
2022-01-18
|
| Locations: |
Profil Institute for Clinical Research, Chula Vista, California, 91911, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01647308
|
